BioLineRx (BLRX) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioLineRx (BLRX) has outperformed Lisata Therapeutics (LSTA) over the past year, losing 49.8% versus a loss of 56.4%. Over five years, LSTA leads with a -94.2% price change compared with -98.2% for BLRX. Lisata Therapeutics is the larger company by market cap ($11.5 million vs $11.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | LSTA |
|---|---|---|
| Share price | $2.22 | $1.06 |
| Market cap | $11.03M | $11.45M |
| 1-day change | -0.18% | -11.67% |
| YTD return | -20.22% | -43.01% |
| 1-year return | -49.77% | -56.38% |
| 5-year return | -98.19% | -94.21% |
| EPS (TTM) | $0.00 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.16 | $5.07 |
| 52-week low | $2.15 | $0.99 |
| Distance from 52-week high | -46.73% | -79.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +892.78% | — |
| Average volume | 16.39K | 302.71K |
| Shares outstanding | 4.98M | 10.80M |
| Employees | 20 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
BLRX vs LSTA FAQ
Which is bigger, BioLineRx or Lisata Therapeutics?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $11.45M compared with $11.03M for BioLineRx (BLRX).
Which stock has performed better over the past year, BLRX or LSTA?
BLRX returned -49.77% over the past 12 months, compared with -56.38% for LSTA (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.